XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization

Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization

CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company’s focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers.

Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successful integration across diverse markets. Mr. Denti has a proven track record of delivering revenue growth and operational efficiency. Most recently, he served as Company Group Chairman, Global Orthopedics, at Johnson & Johnson Medtech.

“I am pleased to welcome Aldo as our new CCO and rejoin forces with him,” said Daniel Scavilla, President and Chief Executive Officer of Dentsply Sirona. “Aldo is a results-oriented innovator with exceptional leadership in navigating dynamic, fast-paced environments and engaging stakeholders worldwide. His expertise will strengthen collaboration across business units and regions, unlock synergies, and support global revenue growth by leveraging our unique portfolio of products and solutions. Aldo will lead our global sales strategy and execution to deliver superior growth, profitability, and customer satisfaction across all regions. Additionally, by bringing our Global Business Units and Commercial Organizations even closer together, the new CCO role will drive a strong focus on the customer and the customer experience. Our new structure will simplify how we work and allow for faster execution.”

Mr. Denti said, “I am honored to join Dentsply Sirona at such an exciting time for the Company. Together with the team, I look forward to advancing our operational goals while strengthening our commercial execution. I strongly believe in the potential of Dentsply Sirona as the world’s largest diversified manufacturer in the dental industry and we will execute on key strategic growth drivers across regions.”

About Aldo M. Denti

Mr. Denti was most recently Company Group Chairman, Global Orthopedics, at Johnson & Johnson Medtech, a main segment of Johnson & Johnson, one of the world’s largest healthcare companies. Prior to his current role, Mr. Denti served as Vice President Global Franchise of Johnson & Johnson Vision. Earlier in his career, Mr. Denti held various leadership roles in EMEA for the Johnson & Johnson orthopedics business and other sales and marketing roles outside Johnson & Johnson. He began his professional path with Pfizer, progressing through sales and marketing leadership roles in Switzerland, the UK and the US. He later worked for Medtronic and Wright Medical in Europe and the US. Mr. Denti speaks six languages and holds a bachelor’s degree with honors from York University in Toronto, Canada, and completed Executive Education Programs at Harvard Business School.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona’s innovative products provide high-quality, effective, and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit for more information about Dentsply Sirona and its products.

Contact Information

Investors:

Wade Moody

Senior Manager, Investor Relations

Press:

Marion Par-Weixlberger

Vice President, Public Relations, Corporate Communications & Brand



EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

 PRESS RELEASE

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleare...

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and ort...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dentsply Sirona Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 March 2026 in which we reassessed the appropriateness of the ratings in the context ...

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought/maiden bought 55,000 shares at between 13.469USD and 14.148USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch